Lopez Laureen M, Otterness Conrad, Chen Mario, Steiner Markus, Gallo Maria F
Clinical Sciences, FHI 360, P.O. Box 13950, Research Triangle Park, North Carolina, USA, 27709.
Cochrane Database Syst Rev. 2013 Oct 26;2013(10):CD010662. doi: 10.1002/14651858.CD010662.pub2.
Unprotected sex is a major risk factor for disease, disability, and mortality in many areas of the world due to the prevalence and incidence of sexually transmitted infections (STI) including HIV. The male condom is one of the oldest contraceptive methods and the earliest method for preventing the spread of HIV. When used correctly and consistently, condoms can provide dual protection, i.e., against both pregnancy and HIV/STI.
We examined comparative studies of behavioral interventions for improving condom use. We were interested in identifying interventions associated with effective condom use as measured with biological assessments, which can provide objective evidence of protection.
Through September 2013, we searched computerized databases for comparative studies of behavioral interventions for improving condom use: MEDLINE, POPLINE, CENTRAL, EMBASE, LILACS, OpenGrey, COPAC, ClinicalTrials.gov, and ICTRP. We wrote to investigators for missing data.
Studies could be either randomized or nonrandomized. They examined a behavioral intervention for improving condom use. The comparison could be another behavioral intervention, usual care, or no intervention. The experimental intervention had an educational or counseling component to encourage or improve condom use. It addressed preventing pregnancy as well as the transmission of HIV/STI. The focus could be on male or female condoms and targeted to individuals, couples, or communities. Potential participants included heterosexual women and heterosexual men.Studies had to provide data from test results or records on a biological outcome: pregnancy, HIV/STI, or presence of semen as assessed with a biological marker, e.g., prostate-specific antigen. We did not include self-reported data on protected or unprotected sex, due to the limitations of recall and social desirability bias. Outcomes were measured at least three months after the behavioral intervention started.
Two authors evaluated abstracts for eligibility and extracted data from included studies. For the dichotomous outcomes, the Mantel-Haenszel odds ratio (OR) with 95% CI was calculated using a fixed-effect model. Cluster randomized trials used various methods of accounting for the clustering, such as multilevel modeling. Most reports did not provide information to calculate the effective sample size. Therefore, we presented the results as reported by the investigators. No meta-analysis was conducted due to differences in interventions and outcome measures.
Seven studies met our eligibility criteria. All were randomized controlled trials; six assigned clusters and one randomized individuals. Sample sizes for the cluster-randomized trials ranged from 2157 to 15,614; the number of clusters ranged from 18 to 70. Four trials took place in African countries, two in the USA, and one in England. Three were based mainly in schools, two were in community settings, one took place during military training, and one was clinic-based.Five studies provided data on pregnancy, either from pregnancy tests or national records of abortions and live births. Four trials assessed the incidence or prevalence of HIV and HSV-2. Three trials examined other STI. The trials showed or reported no significant difference between study groups for pregnancy or HIV, but favorable effects were evident for some STI. Two showed a lower incidence of HSV-2 for the behavioral-intervention group compared to the usual-care group, with reported adjusted rate ratios (ARR) of 0.65 (95% CI 0.43 to 0.97) and 0.67 (95% CI 0.47 to 0.97), while HIV did not differ significantly. One also reported lower syphilis incidence and gonorrhea prevalence for the behavioral intervention plus STI management compared to the usual-care group. The reported ARR were 0.58 (95% CI 0.35 to 0.96) and 0.28 (95% CI 0.11 to 0.70), respectively. Another study reported a negative effect on gonorrhea for young women in the intervention group versus the control group (ARR 1.93; 95% CI 1.01 to 3.71). The difference occurred among those with only one year of the intervention.
AUTHORS' CONCLUSIONS: We found few studies and little clinical evidence of effectiveness for interventions promoting condom use for dual protection. We did not find favorable results for pregnancy or HIV, and only found some for other STI. The overall quality of evidence was moderate to low; losses to follow up were high. Effective interventions for improving condom use are needed to prevent pregnancy and HIV/STI transmission. Interventions should be feasible for resource-limited settings and tested using valid and reliable outcome measures.
由于包括艾滋病毒在内的性传播感染(STI)的流行率和发病率,在世界许多地区,无保护性行为是导致疾病、残疾和死亡的主要风险因素。男用避孕套是最古老的避孕方法之一,也是预防艾滋病毒传播的最早方法。如果正确且持续使用,避孕套可提供双重保护,即预防怀孕和艾滋病毒/性传播感染。
我们研究了改善避孕套使用的行为干预的比较研究。我们感兴趣的是确定与有效使用避孕套相关的干预措施,这种有效性通过生物学评估来衡量,生物学评估可提供保护的客观证据。
截至2013年9月,我们在计算机化数据库中检索了改善避孕套使用的行为干预的比较研究:医学文献数据库(MEDLINE)、人口信息数据库(POPLINE)、考克兰系统评价中心数据库(CENTRAL)、荷兰医学文摘数据库(EMBASE)、拉丁美洲和加勒比卫生科学数据库(LILACS)、OpenGrey、联机公共访问目录(COPAC)、美国国立医学图书馆临床试验注册库(ClinicalTrials.gov)和国际临床试验注册平台(ICTRP)。我们写信给研究者索要缺失的数据。
研究可以是随机的或非随机的。它们研究了改善避孕套使用的行为干预。比较对象可以是另一种行为干预、常规护理或无干预。实验性干预有教育或咨询成分,以鼓励或改善避孕套的使用。它涉及预防怀孕以及艾滋病毒/性传播感染的传播。重点可以是男用或女用避孕套,目标可以是个人、夫妻或社区。潜在参与者包括异性恋女性和异性恋男性。研究必须提供来自测试结果或记录的生物学结果数据:怀孕、艾滋病毒/性传播感染,或用生物学标志物(如前列腺特异性抗原)评估的精液存在情况。由于回忆偏倚和社会期望偏倚的局限性,我们未纳入关于保护或未保护性行为的自我报告数据。在行为干预开始至少三个月后测量结果。
两位作者评估摘要的合格性,并从纳入研究中提取数据。对于二分结局,使用固定效应模型计算Mantel-Haenszel优势比(OR)及95%置信区间(CI)。整群随机试验使用了各种考虑聚类的方法,如多水平建模。大多数报告未提供计算有效样本量的信息。因此,我们按照研究者报告的结果呈现。由于干预措施和结局测量方法存在差异,未进行荟萃分析。
七项研究符合我们的纳入标准。所有研究均为随机对照试验;六项为整群分配,一项为个体随机化。整群随机试验的样本量范围为2157至15614;整群数量范围为18至70。四项试验在非洲国家进行,两项在美国,一项在英国。三项主要以学校为基础,两项在社区环境中进行,一项在军事训练期间进行,一项以诊所为基础。五项研究提供了关于怀孕的数据,这些数据来自妊娠试验或堕胎和活产的国家记录。四项试验评估了艾滋病毒和单纯疱疹病毒2型(HSV-2)的发病率或患病率。三项试验研究了其他性传播感染。试验表明或报告在怀孕或艾滋病毒方面研究组之间无显著差异,但对某些性传播感染有明显的有利影响。两项研究表明,与常规护理组相比,行为干预组的HSV-2发病率较低,报告的调整率比(ARR)分别为0.65(95%CI 0.43至0.97)和0.67(95%CI 0.47至0.97),而艾滋病毒方面无显著差异。一项研究还报告,与常规护理组相比,行为干预加性传播感染管理组的梅毒发病率和淋病患病率较低。报告的ARR分别为0.58(95%CI 0.35至0.96)和0.28(95%CI 0.11至0.70)。另一项研究报告,干预组年轻女性与对照组相比,淋病有负面影响(ARR 1.93;95%CI 1.01至3.71)。这种差异出现在仅接受一年干预的人群中。
我们发现很少有研究且几乎没有临床证据表明促进避孕套双重保护使用的干预措施有效。我们未发现对怀孕或艾滋病毒有有利结果,仅在其他性传播感染方面发现了一些。证据的总体质量为中等至低等;失访率很高。需要有效的干预措施来改善避孕套的使用,以预防怀孕和艾滋病毒/性传播感染的传播。干预措施应在资源有限的环境中可行,并使用有效和可靠的结局测量方法进行测试。